130O The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

Authors :: Rha, S.Y.
Kawazoe, A.
Bai, Y.
Xu, J.
Lonardi, S.
Metges, J-P.
Yanez Weber, P.E.
Wyrwicz, L.S.
Shen, L.
Ostapenko, Y.V.
Bilici, M.
Chung, H.C.
Shitara, K.
Qin, S.
van Cutsem, E.
Tabernero, J.
Li, K.
Shih, C-S.
Bhagia, P.
Janjigian, Y.Y.
Source :: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1521-S1522. 2p.
Publication Year :: 2023

Subjects :: *ESOPHAGOGASTRIC junction
*TRASTUZUMAB
*PEMBROLIZUMAB
*ADENOCARCINOMA
*CANCER chemotherapy
*GASTRIC bypass

Full Text Access

Tools